The results of this study showed that only the median TBIL decrease of patients with liver failure was larger than that of patients with liver cirrhosis after 4 weeks of UCMSC treatment; no statistically significant differences in the levels of ALT or AST, the PTA values or the MELD scores were found between patients with liver failure and patients with liver cirrhosis at all observation weeks. This evidence concerns the gene GPT and liver failure.